...
首页> 外文期刊>Human Pathology >Signal transduction pathway analysis in fibromatosis: Receptor and nonreceptor tyrosine kinases
【24h】

Signal transduction pathway analysis in fibromatosis: Receptor and nonreceptor tyrosine kinases

机译:纤维瘤病中的信号转导途径分析:受体和非受体酪氨酸激酶

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Despite reports of receptor tyrosine kinase activation in desmoid-type fibromatosis, therapeutic benefits of kinase inhibitor therapy are unpredictable. Variability in signal transduction or cellular kinases heretofore unevaluated in desmoid tumors may be responsible for these inconsistent responses. In either case, a better understanding of growth regulatory signaling pathways is necessary to assess the theoretical potential of inhibitor therapy. Immunohistochemical analysis of tyrosine kinases and activated isoforms of downstream signal transduction proteins was performed on a tissue microarray containing 27 cases of desmoid-type fibromatosis and 14 samples of scar; 6 whole sections of normal fibrous tissue were studied for comparison. Platelet-derived growth factor receptor, β type, and focal adhesion kinase 1 were expressed in all desmoid tumors and healing scars but only 80% and 50% of nonproliferative fibrous tissue samples, respectively. Hepatocyte growth factor receptor was detected in 89% of desmoids and all scars tested, but not in any of the fibrous tissue samples. Epidermal growth factor receptor was detected in only 12% of desmoids and not in scar or fibrous tissue. Mast/stem cell growth factor receptor, receptor tyrosine-protein kinase erbB-2, and phosphorylated insulin-like growth factor 1 receptor/insulin receptor were negative in all study cases. Variable levels of phosphorylated downstream signal transduction molecules RAC-α/β/γ serine/threonine-protein kinase, mitogen-activated protein kinase, and signal transducer and activator of transcription-3 were observed in desmoids (58%, 62%, and 67%), scar tissues (100%, 86%, and 86%), and fibrous tissue (33%, 17%, and 17%). These results indicate that tyrosine kinase signaling is active in both fibromatosis and healing scar, but not in most nonproliferating fibrous tissues. Although platelet-derived growth factor receptor, β type, is expressed ubiquitously in desmoids, the kinases driving cell proliferation in desmoids remain unresolved.
机译:尽管有关于在类胶质纤维瘤病中受体酪氨酸激酶激活的报道,但是激酶抑制剂治疗的治疗效果是无法预测的。迄今为止在类胶质瘤中尚未评估的信号转导或细胞激酶的变异性可能是这些不一致反应的原因。无论哪种情况,都需要对生长调节信号通路有更好的了解,以评估抑制剂治疗的理论潜力。酪氨酸激酶和下游信号转导蛋白的活化亚型的免疫组织化学分析是在组织微阵列上进行的,该组织微阵列包含27例类胶质样纤维瘤病和14例瘢痕样品。研究了正常纤维组织的6个完整切片以进行比较。血小板衍生的生长因子受体,β型和粘着斑激酶1在所有皮肤样瘤和愈合性瘢痕中表达,但分别仅在非增生性纤维组织样品中占80%和50%。肝细胞生长因子受体在89%的胶体和所有疤痕中均检出,但在任何纤维组织样品中均未检出。表皮生长因子受体仅在12%的类胶质中检测到,而在疤痕或纤维组织中未检测到。在所有研究病例中,肥大/干细胞生长因子受体,酪氨酸蛋白激酶erbB-2受体和磷酸化胰岛素样生长因子1受体/胰岛素受体均为阴性。在类胶体中观察到可变水平的磷酸化下游信号转导分子RAC-α/β/γ丝氨酸/苏氨酸蛋白激酶,促分裂原活化蛋白激酶以及信号转导和转录激活因子3(58%,62%和67) %),疤痕组织(100%,86%和86%)和纤维组织(33%,17%和17%)。这些结果表明酪氨酸激酶信号传导在纤维瘤病和愈合疤痕中均具有活性,但在大多数非增殖性纤维组织中均无活性。尽管血小板衍生的生长因子受体β型在类胶体中普遍表达,但驱动类胶体中细胞增殖的激酶仍未得到解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号